BioCentury
ARTICLE | Clinical News

ImmunTraCkeR: Clinical trial started

February 9, 2015 8:00 AM UTC

ImmunID began the French PREDICT-ID trial of ImmunTraCkeR to predict response to Yervoy ipilimumab from Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) in about 200 melanoma patients. ImmunTraCk...